Mednet Logo
HomePediatric Hematology/Oncology
Pediatric Hematology/Oncology

Pediatric Hematology/Oncology

Clinical discussions on pediatric blood disorders, childhood cancers, and specialized treatment protocols.

Recent Discussions

Would you stop current immunosuppressive therapy or delay starting immunosuppressive therapy in a patient with aplastic anemia who has been infected with COVID-19?

2 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · Doernbecher Children’s Hospital, OHSU

Not much is known yet about this specific situation—but our growing experience here in New York City suggests it may be safe. We have had several post-BMT patients who were on immune suppression for GVHD become COVID positive who have not had significant problems. Also, we have now treated 8-10 pat...

Is it necessary to prescribe a steroid taper after two weeks of high-dose prednisone (60 mg daily)?

13
6 Answers

Mednet Member
Mednet Member
Neurology · Cedars-Sinai Medical Center

Interesting question. Not being an endocrinologist, I don't have the expertise to advise but the reference below makes the statement that even short-term steroids can be an issue. I suspect that if you have to stop abruptly from 60 mg daily for 2 weeks, it would probably be fine in most instances bu...

For pediatric patients with iron overload (high ferritin and transferrin saturation), do you perform HFE screening first, or proceed to non-HFE gene sequencing upfront to evaluate for HJV mutation as well?

1 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · St. Jude Children’s Research Hospital

Because there is no recommended "screening" scenario for iron overload in pediatrics (especially with no family history), the question for me revolves around "why did the patient get tested in the first place?" If it were a routine screen for iron deficiency, which affects millions of children at an...

What are your top takeaways in Classical Hematology from ASH 2025?

2
5 Answers

Mednet Member
Mednet Member
Hematology · University of Rochester School of Medicine and Dentistry

My top 3 takeaways in classical hematology:1) ITP - much controversy at the education program session about the draft 2025 guidelines, where TPO mimetic + steroids is going to be recommended in the front line. There does not appear to be compelling new data that supports the revision of this guideli...

What screening tools or signs do you use to predict if a cancer patient is near end-of-life?

4
8 Answers

Mednet Member
Mednet Member
Medical Oncology · St Louis Cancer Care LLP

For most of us, long-time practicing oncologists, all we have to do to determine that one of our patients is at the end of their life is to be in the same room with them. No special computer programs or calculators are needed. Just look closely at the patient's current weight, their level of conscio...

How do you approach adjuvant therapy for resected Stage I Ewing sarcoma of the kidney?

1
3 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · University of Saskatchewan

Agree with VDC/IE to start with and monitor electrolytes/renal function. Pediatric protocols use 14 cycles, but there is a high risk of Fanconi syndrome with a single kidney (assuming the patient had a nephrectomy for resection). The COG AEWS1031 protocol allowed the use of C/E - cyclophosphamide/et...

What are some alternatives to dexamethasone for brain edema in patients who are allergic, have an intolerance, or refuse the medication?

8
5 Answers

Mednet Member
Mednet Member
Neurology · Wake Forest School of Medicine

Dexamethasone is one of the most frequently prescribed medications in neuro-oncology clinics. Dexamethasone is often favored over other corticosteroids owing to its lower mineralocorticoid effects and high potency as well as essentially 1:1 oral to IV ratio meaning that we use similar IV and oral do...

How would you manage HHT with ongoing epistaxis despite IV bevacizumab, with a history of superficial thrombosis?

2 Answers

Mednet Member
Mednet Member
Pulmonology · University of Colorado Health

This is a complex situation with a complex answer, and the patient would likely benefit from establishing care at one of the 30 HHT centers of excellence for a more thorough evaluation. If the patient mentioned has only had cautery, we would consider them seeing an ENT at an HHT center of excellence...

Are you altering your use of immune checkpoint inhibitors given the risk of immune-related pneumonitis and the COVID-19 outbreak?

1
2 Answers

Mednet Member
Mednet Member
Medical Oncology · NYU Winthrop Hospital

Nivolumab can be used every 4 weeks rather than every 2 weeks. We have to be flexible and change our approach according to circumstances.

What are your top takeaways from ISTH 2025?

1
2 Answers

Mednet Member
Mednet Member
Hematology · University of Rochester School of Medicine and Dentistry

MAYARI trial - this trial was a single-arm trial for "non-severe" iTTP (excluding patients with significant cardiac or neurologic involvement) where PLEX was only used as a rescue therapy. Patients were started on caplacizumab and immunosuppression with steroids and rituximab. A large number of pa...